Ignite Creation Date:
2024-05-05 @ 9:39 PM
Last Modification Date:
2024-10-26 @ 10:07 AM
Study NCT ID:
NCT00933517
Status:
COMPLETED
Last Update Posted:
2014-03-21
First Post:
2009-07-03
Brief Title:
Assessment of the Efficacy of the Neoadjuvant Combination Chemotherapy-Targeted Therapy in Breast Cancer
Sponsor:
Centre Jean Perrin
Organization:
Centre Jean Perrin
Study Overview
Official Title:
Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere Docetaxel Plus Vectibix Panitumumab in Patients With Operable HR and Her-2 Negative Breast Cancer TVA Study
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TVA
Brief Summary:
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination FEC-TaxotereVectibix
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None